Estimating treatment effects in clinical crossover trials

A. Grieve*, S. Senn, G. G. Koch, N. D. Smith

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)


Some current approaches to modeling crossover thais in two treatments are critically reviewed from the perspective of the practical requirements of the drug developer. Particular attention is paid to the AB/BA design, and the inadequacies of the once popular two-stage procedure are discussed in detail. The use of baseline data is also examined. Both frequentist and Bayesian alternatives to approaches currently advocated are considered and critically compared. It is concluded that it is crucial for the applied statistician working in this field to have an appreciation of the practical medical and pharmacological background.

Original languageEnglish
Pages (from-to)191-233
Number of pages43
JournalJournal of Biopharmaceutical Statistics
Issue number2
Publication statusPublished - 1998
Externally publishedYes


Dive into the research topics of 'Estimating treatment effects in clinical crossover trials'. Together they form a unique fingerprint.

Cite this